A recent study found that second generation of CARs derived from anti-CD22 mAb targeting a membrane proximal C-type Ig domain (m971) has superior antileukemic activity in B-cell acute lymphoblastic leukemia (BCP-ALL), compared with those targeting membrane distal Ig domains [68]. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.